$XXII

22nd Century Group, Inc. (XXII): Entry into a Material Definitive Agreement

22nd Century Group, Inc. (XXII) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 3 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER T

Original reporting
Published Jun 9, 2026, 1:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 1:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$XXII
Neutral
medium confidence
Mentioned
$XXII
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XXIINeutralLow
01

Why it matters

This is primarily a capital-structure event: warrant issuance can create future dilution and may influence trading volatility and financing expectations.

02

Market read

For XXII, the actionable takeaway is the confirmation of a warrant-based financing/issuance mechanism, which can affect dilution expectations and risk premium.

03

What to watch

Traders should verify the actual warrant exercise price, number of shares underlying, and any holder/registration/lock-up terms—these details drive dilution and liquidity impact.

Relevance 6/10Novelty 5/10Timing: Filed June 9, 2026 (SEC 8-K)

Background

The filing is an SEC Form 8-K (Item 1.01 and Item 3.02) describing entry into a material definitive agreement and unregistered equity security issuance via warrants.

Company-level read

Ticker impact

$XXIINeutralMedium confidence
Context

22nd Century Group filed an 8-K disclosing entry into a material definitive agreement tied to issuing common stock purchase warrants.

Expected impact

Near-term bias depends on warrant terms (exercise price/volume), but dilution overhang is the primary risk.

Evidence & confidence

The article is an SEC 8-K with warrant mechanics language, indicating a capital-raising/financing transaction rather than operating performance news.

Market effects

Limited direct sector read-across; this is company-specific financing documentation.

None indicated.

None indicated.

Counterpoint

Warrants can be structured to limit immediate dilution (e.g., higher exercise price or conditional issuance), so the overhang may be less severe than typical.

Key entities

  • 22nd Century Group, Inc.

    Company filing the 8-K and issuing common stock purchase warrants under a material definitive agreement.

  • Common Stock Purchase Warrant

    Warrant instrument described in the exhibit, exercisable over a multi-year window subject to stockholder approval timing.

Related articles

$XXIIMed

22nd Century Group, Inc. (XXII): Results of Operations and Financial Condition

22nd Century Group, Inc. (XXII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 22nd Century Group Reports Second Quarter 2026 Financial Results Advances VLN ® Commercialization Through Expanded Retail Support and Brand-Building Initiatives MOCKSVILLE, N.C., August 13, 2026 —22nd Century Group, Inc. (Nasdaq: XXII), the leader in low-nicotine tob

$SNDKHigh

Sandisk Unveiled an $14 Billion Buyback and Warren Buffett Has Something to Say About It

Sandisk (NASDAQ: SNDK) announced a $14 billion stock buyback, following a $4.5 billion repurchase in Q4. The company's stock has surged 548% in 2026, driven by high demand for NAND flash memory. Sandisk's Q4 revenue reached $9 billion, up 372% year-over-year, with strong growth in its data center business. Warren Buffett supports buybacks when shares are bought below intrinsic value, citing Apple as an example.

$HALOMedAI 9/10

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

Halozyme Therapeutics (HALO) priced a $1.3B upsized offering of 1.50% convertible senior notes due 2033, with a 13-day option for additional $200M. Notes have an initial conversion price of $139.84, a 27.5% premium over the closing price. Proceeds (~$1.275B) will fund capped call transactions, repurchase existing notes, and general corporate purposes. The company expects to close the offering on September 22, 2026.

$CTVAMed

Corteva Fires Back as States Move to Block Corporate Split on Oct. 1

Corteva is defending its planned split into two companies, Corteva and Vylor, against a legal challenge from 21 states. The states argue the split could hinder PFAS liability claims, but Corteva denies wrongdoing and asserts the separation is strategic. Corteva plans to keep its headquarters in Indianapolis, while Vylor will be based in Iowa. The court will decide if the split can proceed as scheduled on Oct. 1.

$CLSKMedAI 8/10

CleanSpark $2.23B Junk Bond for Meta Data Center

CleanSpark is raising $2.23B in junk bonds at ~8.5% yield to fund a Georgia data center for Meta. Meta has committed to a 20-year, $6.6B lease, guaranteeing rent and operating costs. The facility is expected to open in Q4 2027. Morgan Stanley, Goldman Sachs, and Wells Fargo are underwriting the deal. CleanSpark's market value is ~$3.29B.

HighAI 9/10

CoreWeave $3B Convertible Debt Plan

CoreWeave plans a $3B convertible debt sale, with an option for an additional $500M. The company also authorized an at-the-market share sale of up to 35M shares. Proceeds will fund AI compute infrastructure and offset dilution. In Q3, CoreWeave signed deals for compute capacity at an annualized rate of $40M per megawatt, increasing its contracted power capacity to 4.2 gigawatts.